← Back to Strategy

Development Stage

Abingworth also invests in later-stage public and private life science companies, many of which have clinical data.

Our development stage strategy includes Venture Investments in Public Equities (VIPEs). VIPEs are undervalued, usually <$200m market cap, US or European biotech companies in need of finance and active VC guidance and support from the board.

Case Studies

Sierra Oncology

Based in Vancouver, Sierra (NASDAQ: SRRA) is developing and commercialising two drugs for myelofibrosis (MF), a rare bone marrow cancer. Momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of MF, has completed a pivotal Phase 3 clinical study in second line MF patients; positive topline data were announced Q1 2022. The second MF drug is a BET inhibitor. In April 2022 GSK announced the proposed acquisition of SRRA for $1.9b.

Abingworth Role

  • Participated in a $103m financing via our late stage VIPE strategy
  • Andrew Sinclair identified Sierra as an undervalued US biotech in 2019 and joined the board
  • Supported the appointment of new CEO, enhanced the senior team and improved board diversity
AdvanCell

In February 2025, Abingworth co-led a US$112m Series C financing for AdvanCell, a clinical-stage radiopharmaceutical company focused on delivering alpha-emitting radionuclides specifically to the sites of tumors. This financing funded the advancement into Phase 2 of the company’s lead product for metastatic prostate cancer, ADVC001, which targets PSMA to deliver alpha-emitting lead-212 to tumor sites. In July 2026, Abingworth also participated in a $315m Series D financing to fund advancement of ADVC001 toward Phase 3 and expansion of manufacturing and other capabilities.

Abingworth Role

  • Co-led $112m Series C in 2025 and participated in subsequent $315m Series D
  • Active role on Board in determining clinical, manufacturing and financing strategies
  • Active role in strengthening leadership team: Chairman and CEO
Discover our
other strategies

Seed & Early Stage

With close to 40 years of experience investing in novel life science technologies, we understand how challenging it can be to turn a great idea into a great company.

Find out more

Clinical Co-Development

We have pioneered a new approach to partnering with pharmaceutical and biotech companies to help them develop effective new drugs and deliver them to patients in an accelerated manner.

Find out more